در بيماران مبتلا به سرطان كولون قبل و بعد از عمل CEA و SICAM-1 بررسي مقادير سرمي ملكول هاي

The Evaluation of sICAM-1 and CEA Molecules in Colon Cancer Patients Before and After Operation

Introduction: Experimental studies show that some cancer cells including colon cancer cells up regulate the expression of Intracellular Adhesion Molecule-1 (ICAM-1, CD54). In addition, these protein molecules shed from the cell surfaces to the environments that could be detected in culture medium or patient serums. Carcino-embryonic antigen (CEA) has been known as a tumor marker, and is commercially available for detecting and following up the gut malignancy, specially the colon cancer. To determine and compare the serum levels of these molecules in colon cancer patients before and after operation, the present study has been designed. Materials & Methods: a group of patients (66% male and 34% females with age ranges of 56±11 years) who were diagnosed for colon cancer pre- & post-operation in a University hospital was investigated. Their peripheral bloods were taken and their serums were isolated by standard and routine method. Similar procedure was performed for a healthy matched group, and Scientific-Research Journal then the serums for the molecule assessment were obtained using ofShnhed University photometric enzyme immunoassay (or, ELISA). Thirteenth Year, No.62 Results: The pre-operation levels of serum soluble molecule of patients were as follows: sICAM-1=781±219 ng/ml, and CEA=53.6±22.7µg/I. In Apr.-May. 2006 addition, the data obtained from healthy subjects showed the basal levels of sICAM-1=179±39 ng/ml, and CEA=3.6±1.6µg/I. However, after operation the mean ± SD of samples indicated the following: sICAM-1=585±148 ng/ml, and CEA=41.3±26.511g/1. Conclusion: CEA concentration as a tumor marker significantly increased in all the patients, moreover, sICAM-1 was augmented in the patient group four times more than the physiologic levels in healthy control group, the mean assessment of both molecules compared to decrease gradually after operation. Thus, it can be concluded that similar to CEA, sICAM1 can be considered as tumor marker to evaluate and follow up the situation in colon cancer.